A/Prof. Amanda Vincent
1Monash Centre for Health Research and Implementation (MCHRI), Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Australia
Biography:
Clinical Associate Professor Amanda Vincent is a clinician researcher combining clinical practice in menopause with menopause related research, translation and education. She is lead endocrinologist in the Menopause and Early menopause clinics, Monash Health, Clayton, Victoria, Australia with 30 years experience providing clinical care and undergraduate/ post-graduate education in menopause management. She is Head of Early Menopause Research, Monash Centre for Health Research and Implementation https://mchri.org.au/), Monash University and co-leads the Early menopause stream, NHMRC Centre for Research Excellence in Women’s Health in Reproductive life (https://whirlcre.edu.au/). She has publications and successful grant funding in projects, including the Ask Early menopause App (www.askearlymenopause.org). She co-chaired the international guideline group to update the European Society of Human Reproduction and Embryology premature ovarian insufficiency guideline, published in December 2024, and co-designed the accompanying resources. Clinical A/Professor Vincent is Past President of the Australasian Menopause Society and current board member of the International Menopause Society.
Abstract:
Premature ovarian insufficiency (POI), loss of ovarian function before age 40 years, affects almost 4% of women. Spontaneous POI is most commonly idiopathic. However, iatrogenic POI, secondary to chemotherapy, pelvic field radiotherapy or bilateral oophorectomy (BO) is of increasing importance due to the greater number of young cancer survivors and women having risk-reducing BO following positive cancer related genetic testing. POI is associated with an increased risk of chronic disease including cardiovascular disease and dementia; with evidence of greater risk associated with iatrogenic POI secondary to BO. Hormone therapy (HT) is recommended for women with POI; however, iatrogenic POI is often secondary to conditions where HT is contraindicated such as estrogen sensitive cancer. This presentation will explore different causes and consequences of iatrogenic POI, and outline a personalised approach to management with reference to the 2024 ESHRE POI guideline (https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Premature-ovarian-insufficiency).